Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Beth Israel Deaconess Medical Center
Eli Lilly and Company
Pheast Therapeutics
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Jazz Pharmaceuticals
City of Hope Medical Center
AstraZeneca
Memorial Sloan Kettering Cancer Center
Big Ten Cancer Research Consortium
SWOG Cancer Research Network
University of Michigan Rogel Cancer Center
Shanghai Zhongshan Hospital
University of Maryland, Baltimore
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
AIO-Studien-gGmbH
Jazz Pharmaceuticals
Incyte Corporation
Eli Lilly and Company
Emory University
Merck Sharp & Dohme LLC
Leap Therapeutics, Inc.
Toray Industries, Inc
AHS Cancer Control Alberta
Shandong Cancer Hospital and Institute
First Affiliated Hospital of Zhejiang University
Lisata Therapeutics, Inc.